Sujets)
Betacoronavirus , Infections à coronavirus , Maladie grave , Pandémies , Pneumopathie virale , /complications , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , COVID-19 , Comorbidité , Infections à coronavirus/sang , Infections à coronavirus/complications , Infections à coronavirus/mortalité , Infections à coronavirus/thérapie , Femelle , Hospitalisation , Humains , Unités de soins intensifs , Mâle , Adulte d'âge moyen , Pneumopathie virale/sang , Pneumopathie virale/complications , Pneumopathie virale/mortalité , Pneumopathie virale/thérapie , Ventilation artificielle , SARS-CoV-2 , Résultat thérapeutique , WashingtonRésumé
The outbreak of novel coronavirus (SARS-CoV-2) that causes the respiratory illness COVID-19 has led to unprecedented efforts at containment due to its rapid community spread, associated mortality, and lack of immunization and treatment. We herein detail a case of a young patient who suffered life-threatening disease and multiorgan failure. His clinical course involved rapid and profound respiratory decompensation such that he required support with venovenous extracorporeal membrane oxygenation (VV-ECMO). He also demonstrated hyperinflammation (C-reactive protein peak 444.6 mg/L) with severe cytokine elevation (Interleukin-6 peak > 3000 pg/ml). Through treatment targeting hyperinflammation, he recovered from critical COVID-19 respiratory failure and required only 160 hours of VV-ECMO support. He was extubated 4 days after decannulation, had progressive renal recovery, and was discharged to home on hospital day 24. Of note, repeat SARS-CoV-2 test was negative 21 days after his first positive test. We present one of the first successful cases of VV-ECMO support to recovery of COVID-19 respiratory failure in North America.